Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Respiratory Syncytial Virus Infections
Phase 1: Respiratory Tract Infections|Respiratory Syncytial Virus Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01905215 |
NCT01905215 | P1 |
Completed |
Respiratory Syncytial Virus Infections|Respiratory Tract Infections |
2014-04-09 |
2019-03-19 |
Treatments |
|
NCT02360475 |
NCT02360475 | P2 |
Completed |
Respiratory Syncytial Virus Infections |
2015-07-02 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|